In this ANZUP conference highlight, Andrew Weickhardt chats with Betsy Plimack, Chief of the Division of Genitourinary Medical Oncology, Fox Chase Cancer Centre in the US. She talks about the future potential role of genetic mutations in urothelial cancer: can they predict response to treatments or even decide which treatments you should use? They also discuss the use of the new immuno-oncology agents in metastatic kidney cancer: what are the second line options, and how do we measure success of treatments- keep a close ear out for the emerging concept of treatment free survival as the yard stick for the immune-oncology agents.

Ver todos los episodios